Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,400.96
(
-0.16%
)
US TECH 100
28,196.00
(
-1.18%
)
Dow Jones
49,760.56
(
0.11%
)
Brent Oil
104.42
(
-1.27%
)
Bitcoin
80,996.50
(
0.63%
)
News Focus
News Focus
Post# of 447903
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Johnniegalan

Send PM Follow Ignore
Followers 4
Posts 181
Boards Moderated 0
Alias Born 02/13/2013

Johnniegalan

Re: ProLiberty post# 433723

Wednesday, 03/12/2025 8:34:08 AM

Wednesday, March 12, 2025 8:34:08 AM

Post# of 447903
read footnote (4) to the analysis of the R&D spend in the just filed 10k….the line item for “non-clinical” spend has doubled year over year…and descriptor of research into “biological activities of IPE” is utilized…so question, Why would mgt. be doubling it’s efforts in a line item project srudying IPE?……..this is why the stock is undervalued, imo……
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Detailed Quote
Recent AMRN News
More AMRN News